lated on to two coverslips. After 48 hours incubation coverslips were stained with Giemsa and examined for inclusions.
Enzyme immunoassay was performed according to the manufacturer's instructions (IDEIA, Boot's Celltech).
A total of 23 rectal swabs have now been examined. As can be seen in the table, 17 of 23 gave clear positives with the enzyme immunoassay, but only one of these specimens was positive by culture. Urethral swabs were received in parallel with the rectal swabs, which gave discrepant results, and all 16 gave negative culture results. It was clear from these results that the enzyme immunoassay was producing false positive results with rectal swabs. This conclusion was supported by the finding that 15 of 16 swabs taken from randomly selected faeces submitted to the Public Health Laboratory also gave strong positive results in the enzyme immunoassay.
In view of the very strong positive results obtained with faeces and rectal swabs a bacterial antigen cross reacting with the antichlamydial monoclonal antibody seemed unlikely. The organisms listed in table 2, however, were tested in the enzyme immunoassay by making heavy suspensions in chlamydia transport medium. All gave negative results in the enzyme immunoassay, including the strain of Acinetobacter calcoaceticus var anitratus. This organism has been reported3 to give positive results with another enzyme immunoassay for chlamydia (Chlamydiazyme, Abbot Laboratories).
We proceeded to investigate whether protein A of staphylococci could reproduce the effect. Suspensions of six strains were tested. We have therefore been unable to identify the precise mechanism of the false positive results, but it would seem likely that it entails a non-specific binding to mouse immunoglobulin, as in our studies prior absorption of faeces with mouse serum gave a two fold reduction in reading in the enzyme immunoassays, compared with absorption in transport medium.
We have shown that this kit is quite unsuitable for examining rectal swabs, although in fairness the manufacturer's instructions indicate that it is designed for examining genital specimens only. We consider, however, that this problem should be investigated further to ensure that it cannot produce occasional false positive results, with genital specimens. Even if false positive results were uncommon, they would assume importance if the kit were used to screen populations, such as antenatal clinics, which may have a low prevalence of true positive results, rather than the high incidence in the populations examined in reported studies. In a healthy subject HPV infection can induce a transient arrest of erythropoiesis, which does not lead to clinical symptoms because the normal erythrocyte life span exceeds that of any effect of HPV on marrow. In patients with haemolytic anaemias the haemoglobin concentration drops greatly with HPV infection, because the red blood cell life span is shortened.2 In our case the apparent HPV aplastic crisis was similar to those in previous reports,3 but erythroblastopenia associated with HPV in nonhaemolytic anaemia has not been reported as far as we know. It seems that the reticulocytopenia induced by HPV infection can thus worsen a pre-existing anaemia. Our bone marrow findings also showed that HPV, besides its known erythroblastopenic effect, can cause a moderate and transitory decrease in the platelet count, secondary to a hypoplastic effect on the megakaryocytes. Our patient did not have any erythema arthralgia, or vascular purpura, all of which may be seen in HPV infection. 46 We suggest that when a patient with a haemolytic or any other type of anaemia, presents with a rapid and unexplained fall in peripheral blood haemoglobin concentration compared with steady state values, it seems logical to look for HPV infection. JJ For 15 months we have been operating a thyroid function strategy based on ideas of Britton et al,2 but using free thyroxine (Amerlex-M Free T4 RIA kit) as the primary screening test and thyroid stimulating hormone as a discretionary test. The strategy requires a set of decision aiding reference ranges and levels. For detection of hypothyroidism, the relevant values were: euthyroid reference range 9-9-237 pmol/l (0 77-1 84ng/100ml); a therapeutic reference range for patients receiving thyroxine 12 9-308 pmol/I (1-2-39 ng/I00 ml), and a further decision aiding range 123 pmol/l (09 ng/100ml) to select thyroid stimulating hormone in patients presenting with features of hypothyroidism. Thyroid stimulating hormone was also assayed with free thyroxine as the primary investigation, whether or not requested in the following: paediatric cases; patients receiving lithium, amiodarone, or fenclofenac; pregnant patients; those with carcinoma of the thyroid; and goitre with antibodies (we called all these "the problem group.").
Continuous review of our results over 12 months showed that: (i) 22 cases of thyroid stimulating hormone were not tested because, in the absence of clinical details, the patient had not been allocated to the "problem group." Subsequent testing showed that nine of these patients had raised thyroid stimulating hormone values.
(ii) Fifty six patients with low free T4 values had normal thyroid stimulating hormone results, and all of these were acutely sick inpatients with no features of thyroid disease. (iii) Three patients with repeatedly normal serum free T4 concentrations had consistently raised thyroid stimulating hormone values. They all had clinical features of hypothyroidism. On subsequent testing clinically important titres of antithyroxine antibody were detected in the sera (anti-T3 was also detected in one patient). Reassay of hormone after precipitation of interfering immunoglobulin4 gave more accurate free T4 values (table) .
We agree that relevant clinical details with requests for thyroid function testing are nec- 
